15 November 2024
15 November 2024
If confirmed as the HHS Secretary by the US Senate, RFK Jr will oversee federal agencies that dictate healthcare policy in the US.
Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.
Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.
The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable risk-benefit profile”.
Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.
KEBILIDI is delivered via a precise neurosurgical procedure to the putamen of the brain.
The CHMP's decision was influenced by the outcomes of the global Phase III IMROZ trial.
The transaction is subject to conditions under the Hart-Scott-Rodino Antitrust Improvements Act.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
